Ardelyx's Q1 2026 filings reveal revenue growth that outpaced expectations despite continued net losses, mainly due to lasting reimbursement headwinds for XPHOZAH following its inclusion in the ESRD Prospective Payment System. The company continues to commercialize two tenapanor-based therapies—IBSRELA and XPHOZAH—while advancing its pipeline through a pivotal Phase 3 trial for chronic idiopathic constipation and development of next-generation inhibitors. Ardelyx's competitive moat hinges on its proprietary NHE3 inhibitor platform, but market expansion is tempered by regulatory reimbursement shifts and manufacturing dependencies. Upcoming clinical milestones and international licensing partnerships serve as key growth drivers to monitor.